^
    Back
    Association details:
    Biomarker:FGFR2 fusion
    Cancer:Solid Tumor
    Drug:zoligratinib (Debio 1347) (FGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2020
    Title:

    Final results from the phase I study expansion cohort of the selective FGFR inhibitor Debio 1,347 in patients with solid tumors harboring an FGFR gene fusion.

    Published date:
    05/13/2020
    Excerpt:
    Debio 1347 at the recommended dose of 80 mg qd was generally well tolerated and showed signs of activity in solid tumors harboring an FGFR fusion.
    DOI:
    10.1200/JCO.2020.38.15_suppl.3603